# Giorgio Cozza

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 81 papers | 3,062 citations | 30 h-index | 54 g-index |
| 85 ext. papers | 3,648 ext. citations | 5.9 avg, IF | 5.11 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 81 | Developing novel classes of protein kinase CK1 inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. *European Journal of Medicinal Chemistry*, **2021**, 216, 113331 | 6.8 | 3 |
| 80 | In Silico Predicted Antifungal Peptides: In Vitro and In Vivo Anti- Activity. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7, | 5.6 | 2 |
| 79 | Aerobic pyruvate metabolism sensitizes cells to ferroptosis primed by GSH depletion. *Free Radical Biology and Medicine*, **2021**, 167, 45-53 | 7.8 | 3 |
| 78 | An Iron Shield to Protect Epigallocatehin-3-Gallate from Degradation: Multifunctional Self-Assembled Iron Oxide Nanocarrier Enhances Protein Kinase CK2 Intracellular Targeting and Inhibition. *Pharmaceutics*, **2021**, 13, | 6.4 | 1 |
| 77 | Production and purification of homogenous recombinant human selenoproteins reveals a unique codon skipping event in E. coli and GPX4-specific affinity to bromosulfophthalein. *Redox Biology*, **2021**, 46, 102070 | 11.3 | 4 |
| 76 | Inactivation of the glutathione peroxidase GPx4 by the ferroptosis-inducing molecule RSL3 requires the adaptor protein 14-3-3 *FEBS Letters*, **2020**, 594, 611-624 | 3.8 | 16 |
| 75 | Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin. *FEBS Journal*, **2020**, 287, 1850-1864 | 5.7 | 5 |
| 74 | Lack of glutathione peroxidase-8 in the ER impacts on lipid composition of HeLa cells microsomal membranes. *Free Radical Biology and Medicine*, **2020**, 147, 80-89 | 7.8 | 8 |
| 73 | Intracellular protein kinase CK2 inhibition by ferulic acid-based trimodal nanodevice. *International Journal of Biological Macromolecules*, **2020**, 165, 701-712 | 7.9 | 3 |
| 72 | Role of carboxylic group pattern on protein surface in the recognition of iron oxide nanoparticles: A key for protein corona formation. *International Journal of Biological Macromolecules*, **2020**, 164, 1715-1728 | 7.9 | 6 |
| 71 | Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. *Redox Biology*, **2020**, 28, 101328 | 11.3 | 96 |
| 70 | Stealth Iron Oxide Nanoparticles for Organotropic Drug Targeting. *Biomacromolecules*, **2019**, 20, 1375-1384 | 5.9 | 21 |
| 69 | Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression. *Scientific Reports*, **2019**, 9, 1335 | 4.9 | 11 |
| 68 | Benextramine and derivatives as novel human monoamine oxidases inhibitors: an integrated approach. *FEBS Journal*, **2019**, 286, 4995-5015 | 5.7 | 3 |
| 67 | A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease. *EMBO Journal*, **2019**, 38, | 13 | 30 |
| 66 | Development of a yeast-based system to identify new hBRAFV600E functional interactors. *Oncogene*, **2019**, 38, 1355-1366 | 9.2 | 3 |
| 65 | TG2 regulates the heat-shock response by the post-translational modification of HSF1. *EMBO Reports*, **2018**, 19, | 6.5 | 20 |

| | | | |
|---|---|---|---|
| 64 | The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131. *PLoS ONE*, **2018**, 13, e0193479 | 3.7 | 1 |
| 63 | The Acidophilic Kinases PLK2 and PLK3: Structure, Substrate Targeting and Inhibition. *Current Protein and Peptide Science*, **2018**, 19, 728-745 | 2.8 | 9 |
| 62 | The Golgi 'casein kinase' Fam20C is a genuine 'phosvitin kinase' and phosphorylates polyserine stretches devoid of the canonical consensus. *FEBS Journal*, **2018**, 285, 4674-4683 | 5.7 | 10 |
| 61 | Hydrophobic Derivatives of Glycopeptide Antibiotics as Inhibitors of Protein Kinases. *Biochemistry (Moscow)*, **2018**, 83, 1222-1230 | 2.9 | 3 |
| 60 | Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. *Science Signaling*, **2018**, 11, | 8.8 | 37 |
| 59 | Fam20C is under the control of sphingolipid signaling in human cell lines. *FEBS Journal*, **2017**, 284, 1246-1257 | 5.7 | 7 |
| 58 | The landscape of BRAF transcript and protein variants in human cancer. *Molecular Cancer*, **2017**, 16, 85 | 42.1 | 14 |
| 57 | Glutathione peroxidase 4-catalyzed reduction of lipid hydroperoxides in membranes: The polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center. *Free Radical Biology and Medicine*, **2017**, 112, 1-11 | 7.8 | 63 |
| 56 | Covalently bound DNA on naked iron oxide nanoparticles: Intelligent colloidal nano-vector for cell transfection. *Biochimica Et Biophysica Acta - General Subjects*, **2017**, 1861, 2802-2810 | 4 | 32 |
| 55 | The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design. *Pharmaceuticals*, **2017**, 10, | 5.2 | 38 |
| 54 | Casein kinases as potential therapeutic targets. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 319-40 | 6.4 | 59 |
| 53 | Role of Interaction and Nucleoside Diphosphate Kinase B in Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Function by cAMP-Dependent Protein Kinase A. *PLoS ONE*, **2016**, 11, e0149097 | 3.7 | 9 |
| 52 | Glutathione Peroxidase 4 **2016**, 223-234 | | 3 |
| 51 | A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. *Nature Communications*, **2015**, 6, 7227 | 17.4 | 29 |
| 50 | Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at Ser16 to trigger its nuclear localization. *Science Signaling*, **2015**, 8, ra35 | 8.8 | 36 |
| 49 | Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2015**, 1854, 1694-707 | 4 | 12 |
| 48 | Understanding mammalian glutathione peroxidase 7 in the light of its homologs. *Free Radical Biology and Medicine*, **2015**, 83, 352-60 | 7.8 | 28 |
| 47 | A new role for sphingosine: Up-regulation of Fam20C, the genuine casein kinase that phosphorylates secreted proteins. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2015**, 1854, 1718-26 | 4 | 12 |

| | | | |
|---|---|---|---|
| 46 | ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors. *PLoS ONE*, **2015**, 10, e0121378 | 3.7 | 6 |
| 45 | The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation. *BioMed Research International*, **2015**, 2015, 734127 | 3 | 18 |
| 44 | Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity. *Biochemical Journal*, **2015**, 471, 415-30 | 3.8 | 24 |
| 43 | Genuine Casein Kinase: The False Sister of CK2 That Phosphorylates Secreted Proteins at S-x-E/pS Motifs **2015**, 227-237 | | 2 |
| 42 | Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. *Cellular and Molecular Life Sciences*, **2014**, 71, 3173-85 | 10.3 | 36 |
| 41 | The lysine-specific demethylase 1 is a novel substrate of protein kinase CK2. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2014**, 1844, 722-9 | 4 | 8 |
| 40 | Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2). *PLoS ONE*, **2014**, 9, e89176 | 3.7 | 17 |
| 39 | Novel polyamine analogues: from substrates towards potential inhibitors of monoamine oxidases. *European Journal of Medicinal Chemistry*, **2013**, 70, 88-101 | 6.8 | 12 |
| 38 | Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2013**, 1834, 1402-9 | 4 | 15 |
| 37 | Protein disulfide isomerase and glutathione are alternative substrates in the one Cys catalytic cycle of glutathione peroxidase 7. *Biochimica Et Biophysica Acta - General Subjects*, **2013**, 1830, 3846-57 | 4 | 45 |
| 36 | Kinase CK2 inhibition: an update. *Current Medicinal Chemistry*, **2013**, 20, 671-93 | 4.3 | 84 |
| 35 | Detection of phospho-sites generated by protein kinase CK2 in CFTR: mechanistic aspects of Thr1471 phosphorylation. *PLoS ONE*, **2013**, 8, e74232 | 3.7 | 30 |
| 34 | Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A. *Cellular and Molecular Life Sciences*, **2012**, 69, 449-60 | 10.3 | 24 |
| 33 | Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. *Biochemistry*, **2012**, 51, 6097-107 | 3.2 | 105 |
| 32 | Protein kinase CK2 inhibitors: a patent review. *Expert Opinion on Therapeutic Patents*, **2012**, 22, 1081-97 | 6.8 | 56 |
| 31 | Casein hydrolysate for uterine infection treatment: a patent evaluation (WO2011132191). *Expert Opinion on Therapeutic Patents*, **2012**, 22, 575-8 | 6.8 | |
| 30 | A comparison of thiol peroxidase mechanisms. *Antioxidants and Redox Signaling*, **2011**, 15, 763-80 | 8.4 | 161 |
| 29 | Glutathione Peroxidase-4 **2011**, 181-195 | | 2 |

| | | | |
|---|---|---|---|
| 28 | The role of the N-terminal domain in the regulation of the "constitutively active" conformation of protein kinase CK2—insight from a molecular dynamics investigation. *ChemMedChem*, **2011**, 6, 1207-16 | 3.7 | 5 |
| 27 | Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors. *ChemMedChem*, **2011**, 6, 2273-86 | 3.7 | 41 |
| 26 | Inside Cover: The Role of the N-Terminal Domain in the Regulation of the "Constitutively Active" Conformation of Protein Kinase CK2—Insight from a Molecular Dynamics Investigation (ChemMedChem 7/2011). *ChemMedChem*, **2011**, 6, 1134-1134 | 3.7 | |
| 25 | Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. *Biochemistry*, **2011**, 50, 8478-88 | 3.2 | 132 |
| 24 | 8-Hydroxynaphthalene-1,4-dione derivative as novel compound for glioma treatment. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2079-82 | 2.9 | 4 |
| 23 | The dark side of protein kinase CK2 inhibition. *Current Medicinal Chemistry*, **2011**, 18, 2867-84 | 4.3 | 30 |
| 22 | Cystic fibrosis transmembrane regulator fragments with the Phe508 deletion exert a dual allosteric control over the master kinase CK2. *Biochemical Journal*, **2010**, 426, 19-29 | 3.8 | 22 |
| 21 | Isoform specific phosphorylation of p53 by protein kinase CK1. *Cellular and Molecular Life Sciences*, **2010**, 67, 1105-18 | 10.3 | 26 |
| 20 | How druggable is protein kinase CK2?. *Medicinal Research Reviews*, **2010**, 30, 419-62 | 14.4 | 55 |
| 19 | A novel glucosyltransferase from Catharanthus roseus cell suspensions. *Process Biochemistry*, **2010**, 45, 655-659 | 4.8 | 7 |
| 18 | A novel splicing variant encoding putative catalytic alpha subunit of maize protein kinase CK2. *Physiologia Plantarum*, **2009**, 136, 251-63 | 4.6 | 4 |
| 17 | Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 7281-9 | 3.4 | 50 |
| 16 | Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. *Biochemical Journal*, **2009**, 421, 387-95 | 3.8 | 127 |
| 15 | Scouting Novel Protein Kinase A (PKA) Inhibitors by Using a Consensus Docking-Based Virtual Screening Approach. *Letters in Drug Design and Discovery*, **2009**, 6, 327-336 | 0.8 | 6 |
| 14 | ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents. *Anti-Cancer Agents in Medicinal Chemistry*, **2009**, 9, 778-86 | 2.2 | 9 |
| 13 | Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships. *Journal of Medicinal Chemistry*, **2008**, 51, 752-9 | 8.3 | 109 |
| 12 | The selectivity of inhibitors of protein kinase CK2: an update. *Biochemical Journal*, **2008**, 415, 353-65 | 3.8 | 193 |
| 11 | Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. *Current Topics in Medicinal Chemistry*, **2008**, 8, 1555-72 | 3 | 510 |

| | | | |
|---|---|---|---|
| 10 | The regulatory beta subunit of protein kinase CK2 contributes to the recognition of the substrate consensus sequence. A study with an eIF2 beta-derived peptide. *Biochemistry*, **2008**, 47, 8317-25 | 3.2 | 37 |
| 9 | Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?. *Anti-Cancer Agents in Medicinal Chemistry*, **2008**, 8, 798-806 | 2.2 | 8 |
| 8 | Elucidation of the ribonuclease A aggregation process mediated by 3D domain swapping: a computational approach reveals possible new multimeric structures. *Biopolymers*, **2008**, 89, 26-39 | 2.2 | 23 |
| 7 | Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5672-5 | 2.9 | 34 |
| 6 | Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. *ChemBioChem*, **2007**, 8, 129-39 | 3.8 | 104 |
| 5 | Pyrazoloquinazoline Tricyclic System as Novel Scaffold to Design New Kinase CK2 Inhibitors. *Letters in Drug Design and Discovery*, **2006**, 3, 281-284 | 0.8 | 8 |
| 4 | Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. *Journal of Medicinal Chemistry*, **2006**, 49, 2363-6 | 8.3 | 119 |
| 3 | Autophosphorylation at the regulatory beta subunit reflects the supramolecular organization of protein kinase CK2. *Molecular and Cellular Biochemistry*, **2005**, 274, 23-9 | 4.2 | 33 |
| 2 | Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. *Biochemistry*, **2004**, 43, 12931-6 | 3.2 | 82 |
| 1 | Genuine Casein Kinase (Fam20C): The Mother of the Phosphosecretome47-62 | | 2 |